Patients Join NYU Coronavirus Vaccine Clinical Trial - COVID-19 Clinical Trial
Breaking News | COVID-19

Patients Join NYU Coronavirus Vaccine Clinical Trial

Researchers are testing whether four types of so-called “messenger RNA” vaccines can prevent COVID19, the sometimes fatal disease caused by the coronavirus. The hope is the RNA triggers the body to produce proteins associated with the coronavirus. The vaccines are developed by Pfizer and Biopharmaceutical New Technologies. If the vaccines are successful and receive regulatory approval, Pfizer says it can produce millions of doses by the end of the year.NYU continues to recruit healthy candidates to participate in the trial. If someone is between the ages of 18 and 55, and has not been diagnosed with COVID19, they might qualify. 


Moderna Eyes Summer for Phase 3 COVID-19 Vaccine Trial

Moderna is finalizing the protocol for a phase 3 trial of its COVID-19 vaccine with a view to starting the study early in the summer. The establishment of the timeline, which follows FDA clearance to run a phase 2 trial, puts Moderna on track to win approval for its mRNA vaccine mRNA-1273 next year.Having been the first group to start testing a vaccine against SARS-CoV-2, Moderna is now on the cusp of phase 2. With the FDA having completed its review of the IND, Moderna expects to start the 600-subject phase 2 “shortly.”

The phase 3 is following closely behind. Moderna is currently finalizing the protocol for the pivotal trial. If the phase 2 and other preparations go as planned, Moderna could get the pivotal clinical trial underway early in the summer, setting it up to gather the data it needs to potentially win full FDA approval for the vaccine next year. 

https://www.fiercebiotech.com/biotech/moderna-eyes-early-summer-start-for-phase-3-covid-19-vaccine-trial


SHERLOCK’s 1 Hour COVID-19 Detection Test Gets FDA Approval

The FDA granted its first emergency authorization for a CRISPR-based test for COVID-19, developed by Sherlock Biosciences, designed to turn results around in about an hour compared to the four to six hours needed for other molecular diagnostics.

The test is based on the company’s namesake technology, SHERLOCK, short for Specific High-sensitivity Enzymatic Reporter unLOCKing, a Cas13a-based CRISPR system that targets RNA rather than DNA. It looks for an RNA sequence specific to SARS-CoV-2, the virus that causes COVID-19, in patient samples taken from the upper airways with a swab or from airways in the lungs known as bronchoalveolar washing.

https://www.fiercebiotech.com/medtech/sherlock-s-quick-crispr-based-coronavirus-test-gets-emergency-nod

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.